台北中医医学杂志

97.02 台湾中医药发展法回顾与展望
台湾中医药发展法回顾与展望
Retrospect and Prospect of Taiwan Chinese
Medicine and Pharmacy Development Act
施纯全*
台北市中医师公会名誉理事长
义守大学学士後中医学系教授
【摘要】
全球传统医学使用日益增加,WHO 近年陆续公告《2002~2005 年传统医学战略》、《2014~2023 年传统医学战略》、《2011~2020 年西太平洋区域传统医学战略》促进各国将传统医学纳入国家政策与法律架构,以及提高传统医学的品质、有效性及安全性,我国《宪法增修条文》第十条第五项明定「国家应推行全民健康保险,并促进现代和传统医药之研究发展」,并已具有完善的中医药管理体系,但多为细部管理法规,未有促进产业发展之创新研发、人才培训、资金挹注条文,且与韩国《韩医药育成法》与中国《中医药法》相比,较缺少整体政策、经费补助、医药保健、国际交流、产业发展等法规,在行政及财政支援不足,使中医药医疗、产业、研究及人才培育
面临发展瓶颈,爰促使卫生福利部研拟《中医药发展法》,并於2019 年12月31 日公布施行。《中医药发展法》共七章二十四条,分别於中医医疗及照护、中药品质及产业、中医药研究、中医药人才培育各领域确立发展方针,且各条文内容和说明多具中医药特色,可做为各项中医药政策施行法源,另外,首次於法律中定义中医及中药,界定中医学理论及中药学理论范围,有助於未来法律制定或案例裁定。立法後工作主要包含制定中医药奖励或补助、中药药用植物土地承租、中药上市後监测等子办法,以及拟定中医药发展计画,执行过程中需提升财政支援,完善各部会沟通及资源整合机制,并汇整中医药发展之重点议题,建议可叁考韩国三次韩医药发展综合计画成效,以完善未来《中医药发展法》之执行效益。
【关键词】中医药发展法、中医药政策、传统医学战略、韩医药发展法
 
Prof. Chun-Chuan Shih*
School of Chinese Medicine for Post Baccalaureate, I-Shou University, Kaohsiung, Taiwan
【Summary】
Across the world, the demand for traditional medicine services is increasing. The World Health Organization has announced “Traditional Medicine Strategy 2002-2005”, “Traditional Medicine Strategy 2014-2023” and “The Regional Strategy for Traditional Medicine in the Western Pacific 2011-2020” to appeal every ry integrating traditional medicine into national policy and legal framework, and improving the quality, efficacy, and safety of traditional medicine.Although the 10th article on the “Additional Articles of the Constitution of the Republic of China” defined that “The State shall promote universal health insurance and promote the research and development of both modern and traditional medicines”, and Taiwan also has perfect measures of Chinese medicine. Yet, most of Chinese medicine legal are detailed administration,which don’t have articles on innovative R&D, talent training, funding supply.Compared with “Korean Medicine and Pharmaceutics Promotion Act” of Korea,Law of the People’s Republic of China on Traditional Chinese Medicine” of China, legal framework of Taiwan lacks regulations of overall policies, financial subsidies, public health care, international collaboration, industrial development,etc. Furthermore, there are many obstacles on development of medical service,industry, research and talent cultivation of Chinese medicine due to insufficient administrative and financial support. The above reasons have prompted the Ministry of Health and Welfare to develop the “Chinese Medicine and Pharmacy Development Act”, which has announced and implemented on December 31, 2019. “Chinese Medicine and Pharmacy Development Act” has seven chapters and twenty-four articles, which have established development policies of Chinese medicine health care, quality management and industry of Chinese medicine products, research and talent cultivation of Chinese medicine and pharmacy. And the content and description of each article is including characteristics of Chinese medicine and pharmacy, which can be used as the sources of law for the various policies of Chinese medicine and pharmacy. In addition, it is the first definition of Chinese medicine and Chinese medicine products which defining the scope of Chinese medical theory and Chinese pharmacy theory, then it will help draw up regulation or judge the rulings. Enacting regulations on awards or subsides of Chinese medicine and pharmacy, the lease of public lands for the cultivation of Chinese medicinal plants, the post-market monitoring of Chinese medicine products, and formulating development plans of Chinese medicine and pharmacy are important after legislating the Act. During the implementation process, it is necessary to improve funding support, complete communication between various departments and resource integration, focus on the key issue of Chinese medicine and pharmacy development, and refer to the results of the three times Korean medicine and pharmaceutics comprehensive plan in South Korea to improve the effectiveness of future implementations of the “Chinese Medicine and Pharmacy Development Act”.
【Keywords】Chinese Medicine and Pharmacy Development Act, Chinese medicine and Pharmacy policy, Traditional Medicine Strategy, Korean Medicine and Pharmaceutics Promotion Act